Resolvins

Endogenously-generated potent painkilling substances and their therapeutic perspectives

Sungjae Yoo, Ji Yeon Lim, Sun Wook Hwang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The efficacy of many of pain-relieving drugs is based on mechanisms by which the drugs interfere with the body’s natural pain-mediating pathways. By contrast, although it is less popular, other drugs including opioids exert more powerful analgesic actions by augmenting endogenous inhibitory neural circuits for pain mediation. Recently, a novel endogenous pain-inhibitory principle was suggested and is now attracting both scientific and clinical attentions. The central players for the actions are particular body lipids: resolvins. Although research is in the preclinical phase, multiple hypotheses have actively been matured regarding the potency and molecular and neural processes of the analgesic effects of these substances. Consistently, accumulating experimental evidence has been demonstrating that treatment with these lipid substances is strongly effective at controlling diverse types of pain. Treatment of resolvins does not appear to disturb the body homeostasis as severely as many other therapeutic agents that interrupt the body’s natural signaling flow, which enables us to predict their fewer adverse effects. This paper serves as a review of currently documented painkilling actions of resolvins, summarizes the potential cellular and receptor-mediated mechanisms to date, and discusses the many clinical uses for these therapeutic lipids that have not yet been tested. Future scientific efforts will more concentrate to unveil such aspects of the substances and to construct clear proofs of concept for pain relief.

Original languageEnglish
Pages (from-to)664-676
Number of pages13
JournalCurrent Neuropharmacology
Volume11
Issue number6
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Pain
Lipids
Analgesics
Therapeutics
Pharmaceutical Preparations
Therapeutic Uses
Opioid Analgesics
Homeostasis
Research

Keywords

  • Analgesics
  • GPRs
  • Inflammation
  • Pain
  • Resolvin
  • TRP channels

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Resolvins : Endogenously-generated potent painkilling substances and their therapeutic perspectives. / Yoo, Sungjae; Lim, Ji Yeon; Hwang, Sun Wook.

In: Current Neuropharmacology, Vol. 11, No. 6, 01.01.2013, p. 664-676.

Research output: Contribution to journalArticle

@article{2452bcb64da845379d5479f52c616681,
title = "Resolvins: Endogenously-generated potent painkilling substances and their therapeutic perspectives",
abstract = "The efficacy of many of pain-relieving drugs is based on mechanisms by which the drugs interfere with the body’s natural pain-mediating pathways. By contrast, although it is less popular, other drugs including opioids exert more powerful analgesic actions by augmenting endogenous inhibitory neural circuits for pain mediation. Recently, a novel endogenous pain-inhibitory principle was suggested and is now attracting both scientific and clinical attentions. The central players for the actions are particular body lipids: resolvins. Although research is in the preclinical phase, multiple hypotheses have actively been matured regarding the potency and molecular and neural processes of the analgesic effects of these substances. Consistently, accumulating experimental evidence has been demonstrating that treatment with these lipid substances is strongly effective at controlling diverse types of pain. Treatment of resolvins does not appear to disturb the body homeostasis as severely as many other therapeutic agents that interrupt the body’s natural signaling flow, which enables us to predict their fewer adverse effects. This paper serves as a review of currently documented painkilling actions of resolvins, summarizes the potential cellular and receptor-mediated mechanisms to date, and discusses the many clinical uses for these therapeutic lipids that have not yet been tested. Future scientific efforts will more concentrate to unveil such aspects of the substances and to construct clear proofs of concept for pain relief.",
keywords = "Analgesics, GPRs, Inflammation, Pain, Resolvin, TRP channels",
author = "Sungjae Yoo and Lim, {Ji Yeon} and Hwang, {Sun Wook}",
year = "2013",
month = "1",
day = "1",
doi = "10.2174/1570159X11311060009",
language = "English",
volume = "11",
pages = "664--676",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Resolvins

T2 - Endogenously-generated potent painkilling substances and their therapeutic perspectives

AU - Yoo, Sungjae

AU - Lim, Ji Yeon

AU - Hwang, Sun Wook

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The efficacy of many of pain-relieving drugs is based on mechanisms by which the drugs interfere with the body’s natural pain-mediating pathways. By contrast, although it is less popular, other drugs including opioids exert more powerful analgesic actions by augmenting endogenous inhibitory neural circuits for pain mediation. Recently, a novel endogenous pain-inhibitory principle was suggested and is now attracting both scientific and clinical attentions. The central players for the actions are particular body lipids: resolvins. Although research is in the preclinical phase, multiple hypotheses have actively been matured regarding the potency and molecular and neural processes of the analgesic effects of these substances. Consistently, accumulating experimental evidence has been demonstrating that treatment with these lipid substances is strongly effective at controlling diverse types of pain. Treatment of resolvins does not appear to disturb the body homeostasis as severely as many other therapeutic agents that interrupt the body’s natural signaling flow, which enables us to predict their fewer adverse effects. This paper serves as a review of currently documented painkilling actions of resolvins, summarizes the potential cellular and receptor-mediated mechanisms to date, and discusses the many clinical uses for these therapeutic lipids that have not yet been tested. Future scientific efforts will more concentrate to unveil such aspects of the substances and to construct clear proofs of concept for pain relief.

AB - The efficacy of many of pain-relieving drugs is based on mechanisms by which the drugs interfere with the body’s natural pain-mediating pathways. By contrast, although it is less popular, other drugs including opioids exert more powerful analgesic actions by augmenting endogenous inhibitory neural circuits for pain mediation. Recently, a novel endogenous pain-inhibitory principle was suggested and is now attracting both scientific and clinical attentions. The central players for the actions are particular body lipids: resolvins. Although research is in the preclinical phase, multiple hypotheses have actively been matured regarding the potency and molecular and neural processes of the analgesic effects of these substances. Consistently, accumulating experimental evidence has been demonstrating that treatment with these lipid substances is strongly effective at controlling diverse types of pain. Treatment of resolvins does not appear to disturb the body homeostasis as severely as many other therapeutic agents that interrupt the body’s natural signaling flow, which enables us to predict their fewer adverse effects. This paper serves as a review of currently documented painkilling actions of resolvins, summarizes the potential cellular and receptor-mediated mechanisms to date, and discusses the many clinical uses for these therapeutic lipids that have not yet been tested. Future scientific efforts will more concentrate to unveil such aspects of the substances and to construct clear proofs of concept for pain relief.

KW - Analgesics

KW - GPRs

KW - Inflammation

KW - Pain

KW - Resolvin

KW - TRP channels

UR - http://www.scopus.com/inward/record.url?scp=84899503421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899503421&partnerID=8YFLogxK

U2 - 10.2174/1570159X11311060009

DO - 10.2174/1570159X11311060009

M3 - Article

VL - 11

SP - 664

EP - 676

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 6

ER -